11 months ago
Illumina Aims to Triple India Business in 5-7 Years
Illumina, a company that helps analyze genes, is growing its business in India.
They want to increase their business there by a lot in the next few years!
They see India as a place for innovation and growth.
They've opened a center in India and are hiring people to do research there.
The company focuses on diagnosing diseases using genes.
As genetic testing gets cheaper, Illumina is making it easier for hospitals to use.
This will help doctors find diseases earlier and create better treatments, especially for cancer.
Illumina plans to significantly expand its business in India over the next five to seven years.
The company is focusing on India as a hub for innovation and global operations.
They are investing in R&D, including bioinformatics and genomic research in India.
Illumina's technologies are used for genetic disease diagnosis, cancer therapy selection, and more.
The Indian genomics market is projected to grow substantially in the coming years.
- Who
- Illumina Inc.
- What
- Plans to expand its business in India by three to five times over the next five to seven years.
- Where
- India.
- When
- Over the next five to seven years.
- Why
- Due to India's growing market for genetic testing, scientific innovation and global operations.
Key facts
- Company
- Illumina Inc.
- Headquarters
- California, USA
- GCC Employees (Near Term)
- Approximately 500
- India Genomics Market (2024)
- $2.2 billion
- Projected Market Growth (by 2033)
- $9 billion
- R&D Spending (Globally)
- About 20% of revenue ($1+ billion annually)
Quotes
Ankur Dhingra
Chief Financial Officer, Illumina Inc.
“India has the scale, the patient population and the talent pool that make it central to our long-term plans. The work we do here will not just address local healthcare needs but will also contribute directly to our global business.”
businesstoday.in
“Genetic disorders account for 60–70 million incident cases annually in India, and cancer incidence is around 1.5 million a year. Yet, survival rates remain poor. Genomic testing can transform outcomes if adopted more widely.”
businesstoday.in
